ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SAL0120

A development code. Also written as “SAL0120 1mg”, “SAL0120 2mg” and “SAL0120 4mg”.

Its studies are mostly in Hypertension · Renal Insufficiency, Chronic, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 3, since Aug 24, 20262 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals21 open or runningphase 3since Aug 24, 2026Jul 16, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2026First study: phase 2 study in Renal Insufficiency, ChronicFirst studyNCT07716618 · 320 enrolled · China
  2. Aug 24, 2026Phase 3 study in Uncontrolled HypertensionPhase 3 reachedNCT07790120 · 256 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07790120Uncontrolled Hypertension · China3CompletedJul 2, 2026256
NCT07716618Renal Insufficiency, Chronic · China2Active, not recruitingMay 27, 2026320

How it is read

Names in the registry

  • “SAL0120”, 1 entry
  • “SAL0120 1mg”, 1 entry
  • “SAL0120 2mg”, 1 entry
  • “SAL0120 4mg”, 1 entry

Codes read as this program: SAL0120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.